Compare VIR & BL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | BL |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2019 | 2016 |
| Metric | VIR | BL |
|---|---|---|
| Price | $9.49 | $29.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $19.43 | ★ $56.62 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | $68,556,000.00 | ★ $177,031,000.00 |
| Revenue This Year | $270.22 | $12.62 |
| Revenue Next Year | N/A | $10.90 |
| P/E Ratio | ★ N/A | $205.92 |
| Revenue Growth | N/A | ★ 43.78 |
| 52 Week Low | $4.16 | $24.70 |
| 52 Week High | $11.66 | $59.57 |
| Indicator | VIR | BL |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 48.44 |
| Support Level | $8.48 | $29.23 |
| Resistance Level | $10.29 | $30.93 |
| Average True Range (ATR) | 0.42 | 1.97 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 69.78 | 74.48 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.